DNA

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized…

2 years ago

UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling

HAYWARD, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its…

2 years ago

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring…

2 years ago

Nurix Therapeutics Announces Proposed Public Offering

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein…

2 years ago

Akanda Corp. Announces Plan to Integrate Technology Solutions to Capture UK Market

London, United Kingdom--(Newsfile Corp. - April 11, 2024) - On April 4, 2024, Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the…

2 years ago

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the…

2 years ago

Mainz Biomed Reports Full Year 2023 Financial Results

ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of…

2 years ago

Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused,…

2 years ago

Metagenomi to Present at Upcoming Scientific Meetings

-   Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 -   Two Posters at American Society of…

2 years ago

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast…

2 years ago